BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1324 related articles for article (PubMed ID: 19474002)

  • 41. KRAS and BRAF mutations in Serbian patients with colorectal cancer.
    Jakovljevic K; Malisic E; Cavic M; Krivokuca A; Dobricic J; Jankovic R
    J BUON; 2012; 17(3):575-80. PubMed ID: 23033302
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.
    Hsieh LL; Er TK; Chen CC; Hsieh JS; Chang JG; Liu TC
    Clin Chim Acta; 2012 Oct; 413(19-20):1605-11. PubMed ID: 22579930
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.
    Bozzao C; Varvara D; Piglionica M; Bagnulo R; Forte G; Patruno M; Russo S; Piscitelli D; Stella A; Resta N
    Int J Biol Markers; 2012 Dec; 27(4):e366-74. PubMed ID: 23125007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.
    Kotoula V; Sozopoulos E; Litsiou H; Fanourakis G; Koletsa T; Voutsinas G; Tseleni-Balafouta S; Mitsiades CS; Wellmann A; Mitsiades N
    Endocr Relat Cancer; 2009 Jun; 16(2):565-72. PubMed ID: 19190079
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese].
    Zhu XL; Cai X; Zhang L; Yang F; Sheng WQ; Lu YM; Du X; Zhou XY
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):584-9. PubMed ID: 23157824
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H; Eshima K
    Eur J Cancer; 2011 Sep; 47(13):1946-54. PubMed ID: 21531130
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer.
    Morris VK; Lucas FAS; Overman MJ; Eng C; Morelli MP; Jiang ZQ; Luthra R; Meric-Bernstam F; Maru D; Scheet P; Kopetz S; Vilar E
    Ann Oncol; 2014 Oct; 25(10):2008-2014. PubMed ID: 25009008
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.
    Salmaninejad A; Ghadami S; Dizaji MZ; Golchehre Z; Estiar MA; Zamani MR; Ebrahimzadeh-Vesal R; Nowroozi MR; Shakoori A
    Clin Lab; 2015; 61(7):749-59. PubMed ID: 26299074
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.
    Ogino S; Kawasaki T; Kirkner GJ; Loda M; Fuchs CS
    J Mol Diagn; 2006 Nov; 8(5):582-8. PubMed ID: 17065427
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
    Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
    Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
    Ates O; Yalcin S
    Indian J Cancer; 2019; 56(2):176-179. PubMed ID: 31062740
    [TBL] [Abstract][Full Text] [Related]  

  • 53. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers.
    Bond CE; Umapathy A; Ramsnes I; Greco SA; Zhen Zhao Z; Mallitt KA; Buttenshaw RL; Montgomery GW; Leggett BA; Whitehall VL
    Int J Cancer; 2012 Apr; 130(7):1567-76. PubMed ID: 21557216
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
    Zimmer L; Barlesi F; Martinez-Garcia M; Dieras V; Schellens JH; Spano JP; Middleton MR; Calvo E; Paz-Ares L; Larkin J; Pacey S; Venturi M; Kraeber-Bodéré F; Tessier JJ; Eberhardt WE; Paques M; Guarin E; Meresse V; Soria JC
    Clin Cancer Res; 2014 Aug; 20(16):4251-61. PubMed ID: 24947927
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer.
    Kawada K; Nakamoto Y; Kawada M; Hida K; Matsumoto T; Murakami T; Hasegawa S; Togashi K; Sakai Y
    Clin Cancer Res; 2012 Mar; 18(6):1696-703. PubMed ID: 22282467
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 57. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
    Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW
    Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [BRAF gene mutation in wild-type KRAS patients with colorectal cancers].
    Roa I; Game A; Bizama C; Schalper K
    Rev Med Chil; 2014 Jan; 142(1):55-60. PubMed ID: 24861115
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tracing origin of serrated adenomas with BRAF and KRAS mutations.
    Lee EJ; Choi C; Park CK; Maeng L; Lee J; Lee A; Kim KM
    Virchows Arch; 2005 Sep; 447(3):597-602. PubMed ID: 15991007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
    Lu W; Wei H; Li M; Wang H; Liu L; Zhang Q; Liu L; Lu S
    Mol Med Rep; 2015 Jul; 12(1):1219-24. PubMed ID: 25815786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.